Global Systemic Lupus Erythematosus Treatment Market Growth Prospects, Future Industry Landscape 2033 | GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc., Anthera Pharmaceuticals Inc

"The systemic lupus erythematosus treatment market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to advancements in biologics and targeted therapies, increased understanding of disease mechanisms, clinical trials and research initiatives, government initiatives for rare disease treatment, increased awareness and diagnosis of lupus..

The systemic lupus erythematosus treatment market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to emergence of biosimilars for lupus treatmen, integration of digital health solutions, focus on complementary and alternative medicine, innovations in immunomodulatory therapies, patient advocacy and support organizations.. Major trends in the forecast period include combinatorial therapies, personalized medicine approaches, biosimilars in sle treatment, telemedicine in sle management, educational initiatives for patients, global collaborations for lupus research..

Market Overview -
Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its own tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. It is the most common type of lupus and cannot be cured, but medical interventions and lifestyle changes can help control it. Treatment for systemic lupus erythematosus consists mostly of immunosuppressive drugs that inhibit the immune system's activity.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9163&type=smp

Rising Incidence Of Autoimmune Disorders Fuels Growth In The Systemic Lupus Erythematosus Treatment Market
The rising number of autoimmune disorders is expected to propel the growth of the systemic lupus erythematosus treatment market going forward. An autoimmune disease refers to a condition in which a patient's immune system attacks his or her body. An autoimmune disease occurs when the immune system mistakes parts of the body as foreign. The body releases proteins called autoantibodies that attack healthy cells. Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect 10% of the world's population, with 13% of women and 7% of males affected. Furthermore, in October 2021, according to an article shared by the City, University of London, a UK-based public research university, 4 million people in the UK, or 7% of the population, are estimated to have at least one autoimmune disease. Over 80 autoimmune disorders have been found, and their prevalence is increasing annually by 3-9%. Thus, the rising number of autoimmune disorders is driving the growth of the systemic lupus erythematosus treatment market.

Competitive Landscape -
Major companies operating in the systemic lupus erythematosus treatment market report are GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc., Anthera Pharmaceuticals Inc., AstraZeneca plc, Bristol-Myers Squibb Company Inc., F. Hoffmann-La Roche Ltd., ImmuPharma plc, Sanofi SA, Eli Lilly and Company, Amgen Inc., Johnson & Johnson Services Inc., Lycera Corporation, Roche Holding AG, Bayer AG, Novartis International AG, Viatris Inc., Swedish Orphan Biovitrum AB, Union Chimique Belge SA, Biogen Inc., Horizon Therapeutics plc, Gilead Sciences Inc., Daiichi Sankyo Company Limited, EMD Serono Inc., Hoth Therapeutics Inc., Zylo Therapeutics Inc., Kyowa Kirin Co. Ltd., Priothera Ltd., Centessa Pharmaceuticals plc, AbbVie Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited .

Increasing Focus On Product Approvals To Provide Reliable Services To Their Customers
Major companies operating in the systemic lupus erythematosus treatment market are focusing on product approvals such as saphnelo to drive revenues in their market. Saphnelo (anifrolumab-fnia) is a prescription medicine used to treat adults with systemic lupus erythematosus (SLE) ranging from moderate to severe who are also taking other lupus medications. For instance, in August 2021, AstraZeneca PLC, a Sweden-based pharmaceutical company received FDA approval for anifrolumab-fnia (Saphnelo) which is used for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults. This is the first time a type I interferon (type I IFN) receptor antagonist has been approved. The pathophysiology of lupus is largely dependent on type I interferon (IFN), and higher levels of type I IFN signaling are linked to more active and severe disease.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/systemic-lupus-erythematosus-treatment-global-market-report

Key Segments -
The systemic lupus erythematosus treatment market covered in this report is segmented -
1) By Drug: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids, Immunosuppressive Drugs
2) By Route Of Administration: Sub-Cutaneous, Oral, Intravenous
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Sales

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.